SEC Form 4 · accession 0001209191-17-025755
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yamo Deniz
Officer — Chief Medical Officer
Period of report
Apr 3, 2017
Accepted (ET)
Apr 5, 2017 · 5:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $27.43 | Apr 3, 2017 | A | 150,000 | A | — | Apr 2, 2027 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the shares subject to the option shall vest on April 3, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following April 3, 2018, so that all of the shares subject to the option shall be vested after April 3, 2021.